Credo Diagnostics Biomedical Pte. Ltd

Taiwan, April 23, 2022 – Credo Diagnostics presents at 32nd ECCMID, Lisbon, Portugal, on April 23 - 26, 2022.

ECCMID is recognized as the world’s premier Clinical Microbiology & Infectious Diseases event and brings together experts from many fields to present their latest findings, guidelines, and experiences to an audience of 14,000 visitors. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees, allowing for remote and face-to-face opportunities to take part in the multifaceted program.

Credo Diagnostics will showcase the VitaPCR™ instrument, our true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. At the event, we will be providing live hands-on testing and also demonstrate how VitaDataLink, our connectivity software, solves data management issues.

 
We invite all visitors

✓ to come and learn why our covid-19 solution is now used in many parts of the world – from mobile drive through testing stations, to major airports, cruise ships, laboratories, oil drilling platforms, and even onboard the frigates of a major European Navy fleet

✓ to visit us and find out why our solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests
 
We look forward to receiving all visitors to Booth No.2-19.2.

Credo Diagnostics Booth – ECCMID, 2022

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

Singapore, March 24, 2022 - Credo Diagnostics is pleased to announce our participation at the coming 32^nd ECCMID event from April 23 - 26, 2022.  

ECCMID is recognized as the world’s premier Clinical Microbiology & Infectious Diseases event and brings together experts from many fields to present their latest findings, guidelines, and experiences to an audience of 14,000 visitors. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees, allowing for remote and face-to-face opportunities to take part in the multifaceted program.

Credo Diagnostics will showcase the VitaPCR™ instrument, our true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology. At the event, we will be providing live hands-on testing and also demonstrate how VitaDataLink, our connectivity software, solves data management issues.

We invite all visitors

• to come and learn why our COVID-19 solution is now used in many parts of the world – from mobile drive through testing stations, to major airports, cruise ships, laboratories, oil drilling platforms and even onboard the frigates of a major European Navy fleet
• to visit us and find out why our solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests

We look forward to receiving all visitors to our Booth No.2-19.2.

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

Singapore, March 22, 2022 - Credo Diagnostics Biomedical Pte Ltd is pleased to announce the celebration of its 11^th anniversary and official move into a new office at #06-01 Valley Point, Singapore.

“Since our incorporation on 22^nd March 2011, we have grown and weathered many storms. COVID-19 was a game-changing moment as we were given a chance to participate in the fight against the pandemic. Our VitaPCR™ Instrument and COVID-19 related assays are now used in many parts of the world – from mobile drive-through testing stations to major airports, cruise ships, laboratories, oil drilling platforms, and even onboard the frigates of a major European Navy fleet. The Credo solution is easily associated by many users as the solution for quick and accurate point-of-care molecular tests” said Dr. Wong Jr. Winston, Chairman, and CEO of Credo Diagnostics Biomedical.

“Today, it is a great honour to see our solution accepted and requested by users around the world. We strive to continually provide the best solutions to our customers and will never stop innovating.” continued Dr. Wong Jr. Winston.

To mark our 11^th anniversary, Credo Diagnostics Biomedical will embark on the next phase of growth – by launching our next range of assays and continuing our mission “Affordable Advanced Medical Technology for All.”

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.